NNVC
NanoViricides, Inc.1.2900
+0.0600+4.88%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
27.82MP/E (TTM)
-Basic EPS (TTM)
-0.50Dividend Yield
0%Recent Filings
8-K
10-K
FY2025 results
NanoViricides ended FY2025 with no revenues and a net loss of $9.5 million, up from $8.3 million last year, driven by higher R&D on NV-387 and investor outreach costs, while cash dipped to $1.6 million amid ongoing clinical pushes. The standout momentum came from NV-387, the broad-spectrum antiviral that aced Phase Ia/Ib safety trials with zero adverse events in healthy volunteers, paving the way for dual Phase II trials: one targeting MPox in the Democratic Republic of Congo, where preliminary ethics approval signals Q4 acceleration versus Q3 planning, and another innovative basket trial for viral acute respiratory infections (ARI/SARI) to test efficacy across Influenza, RSV, and Coronaviruses without virus-specific delays. Q4 saw sequential gains in manufacturing scale-up, doubling NV-387 batch sizes to 6kg for smoother trial supply, while animal models confirmed superior lung protection over approved Influenza drugs, hinting at margin-like efficiency in broad-spectrum action. Liquidity remains tight with $3 million credit access, but no capex shifts or dividends; the year closed eyeing non-dilutive biodefense grants for Smallpox under FDA's Animal Rule. Yet regulatory hurdles in emerging markets could stall quarterly momentum.
10-Q
Q3 FY2025 results
NanoViricides posted a Q3 net loss of $2.2M, up 20% y/y, with operating expenses climbing to $2.2M from $1.9M amid higher R&D and investor outreach costs. For the nine months, the net loss widened to $7.4M from $5.9M, driven by $4.4M in R&D and $3.1M in G&A, while cash burned $6.8M in operations versus $4.8M last year. Equity raises netted $4.6M, leaving $2.5M in cash against $1.2M liabilities, but liquidity strains persist with no revenue and ongoing Phase II prep for NV-387 in MPox and RSV trials. No debt drawn from the $3M related-party line maturing March 2026. Cash won't last 12 months without fresh funding.
10-Q
Q2 FY2025 results
NanoViricides narrowed its Q2 operating loss to $2.1M from $2.2M a year earlier, while YTD operating loss widened to $5.2M from $4.2M, driven by higher general and administrative costs tied to investor outreach. No revenue yet, but R&D spend held steady at $3.1M YTD, supporting Phase I completion of broad-spectrum antiviral NV-387 with zero adverse events. Cash dipped to $4.0M from $4.8M at fiscal year-end, offset by $4.0M from equity sales; free cash flow not disclosed in the 10-Q. The $3M related-party line of credit remains undrawn through March 2026. NV-387 advances to Phase II trials for MPox and RSV, building on strong animal data. Yet regulatory hurdles in funding-strapped biotech demand careful navigation.
8-K
Annual meeting approves board, auditors
NanoViricides held its 2024 annual stockholder meeting on December 7, with 47.1% of voting shares present. Shareholders re-elected Theodore Rokita as Class I director and Makarand Jawadekar and Brian Zucker as Class II directors for two-year terms, while ratifying EisnerAmper LLP as auditors for the fiscal year ending June 30, 2025. Directors won handily despite some opposition. The vote signals steady governance continuity.
IPO
Employees
Sector
Industry
COCP
Cocrystal Pharma, Inc.
0.98-0.04
CVAC
CureVac N.V.
4.82-0.18
GOVX
GeoVax Labs, Inc.
0.29-0.05
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NUVB
Nuvation Bio Inc.
8.66+0.15
NVAX
Novavax, Inc.
6.54-0.04
VIR
Vir Biotechnology, Inc.
6.48-0.24
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VXRT
Vaxart, Inc.
0.37+0.01